HLA-G and Immune Evasion in Cancer Cells

Acquisition of novel gene products or new antigens in cancer cells elicits a host immune response that results in selection pressure for tumor clones to evade immunosurveillance. Similar to maternal–fetal tolerance and allotransplantation acceptance, upregulation of HLA-G expression has been found as one of the mechanisms that are programmed in cancer cells. HLA-G expression is frequently detected in a wide variety of human cancers and its protein levels negatively correlate with poor clinical outcome. The immune inhibitory effect can be achieved by binding of HLA-G molecules to the immunoglobulin-like inhibitory receptors that are expressed on the immunocompetent cells at all stages of the immune response. This review summarizes recent studies of HLA-G expression in human cancer, with a special focus on the molecular mechanisms that underlie how HLA-G molecules facilitate tumor cell evasion of the host immune response, and presents new directions for developing HLA-G-based diagnosis/therapeutics.

Key Words:  cancer , HLA-G , immunosurveillance , therapeutics

No full text is available. To read the body of this article, please view the PDF online.